AVAC’s Take

A lot happened in New York City in the last 10 days of September—so much, that we’re still absorbing it more than a month later. The Pope visited and the city’s finest hotels filled with heads of state gathering for the UN General Assembly. On a glittering boat circling the island of Manhattan, the irreplaceable International Gay and Lesbian Human Rights Coalition celebrated victories and 25 years of tireless struggle, and girded for future work with a new name, Outright International.

Oh yes, and somewhere in there, there was some news about AIDS, wasn’t there?

Indeed there was. In quick succession, the US government and the World Health Organization made announcements that will, ideally, have a profound effect on the course of the epidemic. US President Barack Obama announced new targets for the PEPFAR program on September 27, and then on September 30 the WHO released a new “early-release guideline”, which recommended immediate antiretroviral treatment (ART) for all people living with HIV and PrEP for all people at substantial risk of HIV.

And all of this happened in the context of the UN General Assembly focused on Sustainable Development Goals (SDGs), which map objectives out to 2030.

Those September developments aren’t all that we’re paying attention to. In mid-October, UNAIDS issued long-awaited “Fast-Track” targets for VMMC, PrEP, rights-based interventions, prevention for key populations—and more. These targets complement the 90-90-90 goals focused on ART for people living with HIV.

Here at AVAC, we know all too well that New York City isn’t the center of the world. But for that week or so in September it felt like everything that defines our work had converged in the Big Apple: pageantry, prayers, press attention and, as always, activists who understand that celebration is the best way to prepare for what comes next.

And that, indeed, is the question: what comes next?

In this issue of Px Wire, we try to answer that question.

—AVAC

Data Dispatch

» Targets, guidelines and the implementation-financing “box-step”

With back-to-back announcements from the WHO, PEPFAR and UNAIDS, it’s fair to ask: Which matters the most and why? The answer is: They all do, but for different reasons. The PEPFAR announcement fills a gap that US-based advocates have noted for some time—an absence of overarching goals for the program. (For an extensive look at AVAC’s take on why targets matter, check out AVAC Report 2014/5: Prevention on the Line at www.avac.org/report2014-15.) In the absence of goals, there’s no way to measure progress, to forecast the future, or to make sound financial investments. President Obama’s announcement begins to fill that gap.

The UNAIDS targets released in October also fill a key gap in that they rebalance the global conversation around what is needed to begin to end the epidemic. UNAIDS calls for three million individuals on PrEP annually—and for VMMC the target is 27 million additional procedures by 2020. Before these targets existed it appeared that the ART-focused 90-90-90 goals were sufficient to bring the epidemic to an end. This wasn’t accurate, and the new UNAIDS targets are a key step to correcting the global course.

Importantly, a target from a funder like PEPFAR is tied to money. The UNAIDS targets aren’t. Nor, of course, are WHO guidelines or SDG goals. But they do provide a greenlight for countries to make their own ambitious plans. And they are important tools for enforcing accountability, a major theme of the SDGs.

Entities that issue bold targets must be held accountable for quantifying and mobilizing resource gaps. PEPFAR funds part of the global AIDS response but, with its new focus on specific geographic regions within countries, it can’t be said to work across an entire country, let alone the world. So in every country, including ones with PEPFAR funding, there is a question of whether there are adequate resources. Without a guideline, the “ask” for resources isn’t possible, but without the resources, the guideline isn’t very relevant at all.

The ideal scenario is one where normative guidelines, implementer targets, country programs and resources all align.
The New Context for HIV Prevention: Is the world on target?

With recent announcements from the WHO, PEPFAR and UNAIDS, there’s much to celebrate. Global leadership now recognizes the need for universal access to ART, while also putting PrEP, VMMC and combination prevention at the core of a comprehensive response. But these targets also highlight current challenges. The coverage gap for ART is wider, and recognition of VMMC comes at a time when scale-up is slowing down. There’s no road map for rolling out PrEP. For AVAC’s take on how the situation for key activities stacks up against a checklist of “must-have” metrics, see below.
A greenlight for PrEP

Until mid-October, much of the world was in a PrEP holding pattern. The WHO hadn’t endorsed widespread use, and UNAIDS had published documents in anticipation of upcoming guidance but had not issued any targets for PrEP, or any other non–ART strategy for that matter. Now, everything has changed—at least at the global level. Both WHO and UNAIDS have shown leadership in recognizing the role of a tool that can be key, particularly for individuals who can’t always negotiate condom use. The question now is: Will countries take action by developing PrEP introduction plans and building funding for it into government budgets, GFATM proposals and PEPFAR plans? For now, it’s unclear. The good news is that many stakeholders are ready to expand ongoing advocacy for national action to ensure that every country invests in exploring an option that has the potential to prevent many new cases of HIV. Want to know what’s next in the access roadmap in your country? Visit our revamped PrEP Watch website (details in box at right).

Tailor advocacy to the target

It’s critical for there to be guidance, resources and targets. Even better is a situation in which it’s clear how to reach the target. The honest truth is that, with the exception of the VMMC target, it’s unclear how to reach any of the new PEPFAR targets. ART is a familiar intervention. But in most parts of the world, programs have not been designed to offer, initiate and support treatment in healthy people.

The new DREAMS initiative led by PEPFAR calls for a 40 percent reduction in new HIV acquisition, by 2017, in young women aged 15-24 in 10 focus countries. This focus and ambition is exciting. But success depends on a clear-eyed approach. It’s not clear how to achieve this target or even how to measure impact in such a short timeframe. There’s a high probability that more will be achieved in a failed attempt to reach this target than ever would have been accomplished without it. But it’s important for advocates to both inform and monitor how DREAMS countries add clarity and evidence to their plans.

Back to those VMMC targets. PEPFAR’s peak performance was 2.8 million in a single year. It won’t be close to that in 2017. PEPFAR doesn’t need to, and indeed shouldn’t, pay for the pursuit of global VMMC targets on its own. UNAIDS has called for a total of 27 million additional procedures by 2020. This works out to more than five million procedures per year—two million more than have ever been performed. AVAC welcomes ambitious goals—as long as global leadership is also shown in resource mobilization.

The Global Fund should ensure that country concept notes fill the space. And PEPFAR and UNAIDS should become vocal, determined VMMC resource-mobilization advocates in country and global forums.

Time for a new prevention architecture

We hope the foregoing points sound pragmatic, not pessimistic. Because the good news about the WHO guideline and the new PEPFAR and UNAIDS targets is that they really do put prevention at the center of the AIDS response. And it’s time for the global and country-level architecture of budgeting, planning and monitoring to follow suit. ART for people living with HIV has a clinical benefit for the individual and, if it results in virologic suppression, it is potent prevention. Since ART has historically been budgeted separately from prevention (and since PMTCT has historically been included in prevention) it’s going to be hard, if not impossible, to track impact and create comprehensive prevention plans without an integrated approach. This approach could gather viral load data and calculate the prevention impact (related to virologic suppression) of treatment spending, and then link this information to prevention spending in a conversation and planning process that also looks at VMMC, PrEP and strong testing linkages—at the same time.

It hasn’t been done before, but that doesn’t mean it’s impossible. The treatment and prevention gaps actually widen with these guidelines and beg huge implementation challenges, to put it mildly. But the scientific evidence and now these targets and normative guidance should push us all to talk about how to realign the resources we have, even while we advocate for more.

Visit our redesigned website, www.prepwatch.org—a clearinghouse for PrEP data, additional research, cost, access and advocacy efforts across the globe.

About AVAC

AVAC works to accelerate the development and global delivery of HIV prevention tools. To receive regular updates via email sign up at www.avac.org/signup.

423 West 127th St., 4th Floor • New York, NY 10027 USA  Telephone +1 212 796 6423 • www.avac.org